Core Insights - Jiangsu Dingtai Pharmaceutical Research (Group) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Citigroup and Haitong International as joint sponsors [1] Company Overview - Established in 2008, Dingtai Pharmaceutical is a new type of Contract Research Organization (CRO) that provides integrated solutions based on disease biology for global pharmaceutical companies and research institutions [3] - The company has transitioned from a traditional CRO role to a strategic R&D partner, offering comprehensive non-clinical safety, efficacy, and drug metabolism and pharmacokinetics (DMPK) research, as well as integrated clinical trial services from proof of concept to pivotal trials [3] - Dingtai Pharmaceutical focuses on clinical value and has accumulated deep expertise in cardiovascular metabolic diseases, central nervous system (CNS) diseases, ophthalmology, autoimmune diseases, and oncology [3] Market Position - According to Frost & Sullivan, Dingtai Pharmaceutical is the largest CRO in China for non-clinical research in cardiovascular metabolic diseases based on projected revenue for 2024 [3] - The company has built one of the most comprehensive non-human primate (NHP) disease model portfolios in China, ranking as the third-largest CRO in the field of efficacy research [4] Services and Capabilities - Dingtai Pharmaceutical's biomarker and translational medicine platform offers immunology, cellular, and molecular testing, supported by industry-leading sensitivity, robustness, and throughput characteristics in mass spectrometry bioanalysis [4] - The company monitors the progress of new therapies in key disease areas to anticipate industry trends and strategically expand its technical capabilities [4] - Dingtai Pharmaceutical supports clinical trials involving various advanced therapies, particularly in cancer treatment, through a comprehensive multimodal evaluation framework [4] Client Base and Achievements - The company has established a loyal and diverse client base, including commercial-stage pharmaceutical companies, early-stage biotech firms, and renowned research institutions [5] - Since its inception until October 24, 2025, Dingtai Pharmaceutical has provided non-clinical services to over 700 clients and clinical services to over 130 clients, assisting in obtaining more than 200 approvals from the National Medical Products Administration (NMPA) and over 40 approvals from overseas regulatory agencies [5] Financial Performance - Revenue figures for the company are as follows: approximately RMB 725 million in 2022, RMB 767 million in 2023, RMB 713 million in 2024, and RMB 377 million for the six months ending June 30, 2025 [6] - Profit figures for the same periods are approximately RMB 143 million in 2022, a loss of RMB 51.9 million in 2023, a loss of RMB 252 million in 2024, and a profit of RMB 64.7 million for the six months ending June 30, 2025 [6]
鼎泰药物递表港交所 为中国心血管代谢疾病非临床研究领域的第一大CRO
Zhi Tong Cai Jing·2025-11-02 09:28